Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 7/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1426879 | 1.00 | MCHR1 (0.50) | MCHR1KCNH2PARP1PARP2CHRM4 | |
| SCHEMBL1426784 | 0.91 | MCHR1 (0.51) | MCHR1KCNH2PARP1PARP2MET | |
| SCHEMBL1426782 | 0.91 | MCHR1 (0.51) | MCHR1KCNH2PARP1PARP2MET | |
| SCHEMBL1426571 | 0.91 | MCHR1 (0.51) | MCHR1KCNH2PARP1PARP2 | |
| SCHEMBL1426569 | 0.91 | MCHR1 (0.51) | MCHR1KCNH2PARP1PARP2 | |
| SCHEMBL1426896 | 0.87 | MCHR1 (0.50) | MCHR1KCNH2PARP1PARP2MET | |
| SCHEMBL1426897 | 0.87 | MCHR1 (0.50) | MCHR1KCNH2PARP1PARP2MET | |
| SCHEMBL1426400 | 0.85 | KCNH2 (0.57) | MCHR1KCNH2PARP1PARP2 | |
| SCHEMBL1426396 | 0.85 | KCNH2 (0.57) | MCHR1KCNH2PARP1PARP2 | |
| SCHEMBL1426318 | 0.85 | MCHR1 (0.51) | MCHR1KCNH2PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301936-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | claimed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | claimed |
| EP-2301936-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MCHR2, MCHR1, ADRB2 | MCHR1 2/4885KCNH2 499/4885PARP1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.